DaVita Inc. (NYSE:DVA) Given Consensus Recommendation of “Hold” by Analysts

Shares of DaVita Inc. (NYSE:DVA) have been assigned an average rating of “Hold” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $203.1667.

A number of brokerages have recently commented on DVA. Barclays raised their target price on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research note on Wednesday. UBS Group increased their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday. TD Cowen upped their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Finally, Truist Financial increased their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th.

DaVita Price Performance

NYSE DVA opened at $229.25 on Friday. DaVita has a 1-year low of $101.00 and a 1-year high of $239.64. The firm has a market capitalization of $14.72 billion, a P/E ratio of 21.27, a P/E/G ratio of 0.76 and a beta of 0.88. The business’s 50-day simple moving average is $202.89 and its 200-day simple moving average is $159.82.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts expect that DaVita will post 15.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On DaVita

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Value Investment Professionals LLC boosted its holdings in DaVita by 2.0% in the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the last quarter. Kesler Norman & Wride LLC increased its holdings in DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares during the last quarter. Gen Wealth Partners Inc raised its position in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after purchasing an additional 80 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares in the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of DaVita by 4.4% during the 4th quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after buying an additional 99 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.